Heparan sulfate (HS), dermatan sulfate (DS) and heparin are glycosaminoglycans (GAGs) that serve as key natural and pharmacological anticoagulants. During normal clotting such agents require to be inactivated or neutralised. Several proteins have been reported to facilitate their neutralisation, which reside in platelet a-granules and are released following platelet activation. These include histidine-rich-glycoprotein (HRG), fibrinogen and high-molecular-weight kininogen (HMWK). Zinc ions (Zn 2+ ) are also present in a-granules at a high concentration and participate in the propagation of coagulation by influencing the binding of neutralising proteins to GAGs. Zn 2+ in many cases increases the affinity of these proteins to GAGs, and is thus an important regulator of GAG neutralisation and haemostasis. Binding of Zn 2+ to HRG, HMWK and fibrinogen is mediated predominantly through coordination to histidine residues but the mechanisms by which Zn 2+ increases the affinity of the proteins for GAGs are not yet completely clear. Here we will review current knowledge of how Zn 2+ binds to and influences the neutralisation of GAGs and describe the importance of this process in both normal and pathogenic clotting.
Introduction
Glycosaminoglycans (GAGs) including heparin sulfate (HS), dermatan sulfate (DS) and heparins are key molecules involved in several biological processes, including coagulation where they play an important anticoagulant role. 1 HS is mostly synthesised by endothelial cells, where it lines the endothelium and participates in its intrinsic anticoagulant properties. 2 DS is mostly synthesised in the sub-endothelium and is exposed to plasma proteins during injury. 3 Heparins are synthesised by mast cells and may also be secreted following tissue injury, 4, 5 however, this has been disputed by some. [6] [7] [8] The main relevance of heparins are in clinical settings, where they and heparin-based drugs are important agents used in the clinical treatment of coagulatory disorders. 9 As GAGs are physiologically found in a variety of sizes, heparin drugs are administered clinically as unfractionated heparin (UFH), which have not been cleaved or separated by size or as low molecular weight heparin (LMWH), which are generally o8000 Da. 10 All GAGs exercise their anticoagulant activity through their binding to serpins. 1 The main partners for HS and heparin are antithrombin (AT) and heparin cofactor II (HCII) while DS can only bind to HCII. 1 When bound together, the GAGs can change the conformation of the reactive centre loop of the serpin to increase the inhibitory activity of the molecule. 11 During normal coagulation, when clotting is required, anticoagulant GAGs are neutralised by several proteins, including histidine-richglycoproteins (HRG), high-molecular-weight kininogen (HMWK) and fibrinogen. 10, 12 After iron, zinc is the most abundant transition metal in the human body. Zinc is an important element in the body, playing key structural and catalytic roles as well as functioning as an extracellular and intracellular signalling molecule. Ionic zinc (Zn 2+ ) is essential for physiological processes such as cell replication, tissue growth, immune functioning and coagulation. [13] [14] [15] The importance of Zn 2+ is best illustrated by the cases of zinc deficiency, which is defined as having a total plasma zinc concentration below 0.7 mg L À1 (normal range is 0.8-1.0 mg L À1 ). [16] [17] [18] Zinc deficiency is associated with coagulatory abnormalities including a reduced ability for platelets to aggregate and longer bleeding times, which in most cases can be quickly corrected by zinc supplementation without secondary effects. [16] [17] [18] In addition to the resting plasma Zn 2+ level, during coagulation platelets release Zn 2+ stored in their a-granules, thus initiating a signalling process. [19] [20] [21] During this process Zn 2+ acts to propagate several anticoagulation pathways as well as both pro-and anti-fibrinolytic pathways. 13 In addition to Zn
2+
, platelet a-granules also release numerous proteins that impact on coagulation, among which are HRG, HMWK and fibrinogen. 10, 22 These proteins have both the ability to bind Zn 2+ and to bind and neutralise anticoagulant GAGs. [23] [24] [25] [26] [27] [28] [29] [30] The mechanisms and impact by which Zn 2+ influences GAG binding and neutralisation by these proteins is reviewed here. Zn 2+ that they sequester into two pools, the cytoplasm (around 60% that is used to regulate platelet function) 21, 37 and the a-granules (around 40%). 21 Variations of the total amount of Zn 2+ present in the plasma affect the quantity present in the platelets, as well as the distribution of the two pools. 37 There is still some uncertainty as to how Zn 2+ is incorporated into the platelets. Some Zn 2+ may be incorporated when the Zn
-bound fibrinogen-coagulation factor XIII(a 2 ) complex enters the platelet through binding to fibrinogen receptors. 37 However the main mechanism for Zn 2+ entry into platelets is likely to be through Zn 2+ transporters (as reviewed by Taylor and Pugh); 38 the exact mechanism however remains to be elucidated. When platelets are activated, up to half of the a-granule Zn 2+ pool is released. 35, 36 This action has been reported to increase the labile/free plasma Zn 2+ concentration to 7-10 mM in the proximities of activated platelets. 35 has been marked as an initiator of the contact activation pathway of coagulation through enhancing the interactions of contact proteins with polyanionic surfaces and their assembly on endothelial cells and platelets. 13 Zn 2+ enhances platelet aggregation and activation by increasing internal platelet signalling and external binding of platelets to their ligands. 13 It also enhances fibrin formation while also attenuating thrombin activity. 13 , triggers conformational changes that have the potential to affect their interactions with their ligands. 45 The effect of Zn 2+ was not examined in their study but is likely to mimic the effects of these other metal ions. As both Ca 2+ and Zn 2+ are released from platelets during coagulation and participate in the regulation of coagulation, this is of particular interest as it is likely that this mechanism alters the anticoagulant activities of heparin and HS following platelet activation. 21 UFH has been shown to bind Zn 2+ via two different mechanisms: the first represents a high-affinity form of binding (the equilibrium constant is 976 M
À1
) whilst the second is a low-affinity form of binding that only occurs at high Zn 2+ concentrations (the equilibrium constant is 241 M
). 46 Both binding events are entropy driven and both involve sulfated side chains on the GAGs. The exact stoichiometry of these binding events has not yet been precisely defined but it is assumed that the first mode of binding involves one zinc ion binding per disaccharide and that the second mode intervenes only after saturation is reached for the first one. 46 GAGs interact with basic amino acids on proteins, generally lysine and arginine side-chains that are not normally affected by the presence of cations. 47 Those cations however often bind to exposed histidines, which are positively charged, and this binding may then facilitate the binding of the protein to GAGs by reducing the electrostatic repulsion between the two of them. 47 As Zn 2+ is released at the beginning of the coagulation process, its effect on GAG neutralisation reduces anticoagulation and promotes clotting.
Impact of Zn 2+ on protein-GAG interactions
Numerous proteins in plasma have the ability to neutralise anticoagulant GAGs, as reviewed previously. 10 50 and 12-24 mM for fibrinogen). 51 Their specific roles in coagulation are diverse. Fibrinogen plays a prominent role as when it is cleaved, it polymerises to form fibrin clots. 52 HRG plays a regulatory role by inhibiting fibrinolysis in addition to being incorporated in blood clots, 53 while HMWK is a key activator of the contact activation pathway of the coagulation cascade. 54 Thus all three proteins are in contact with endothelial GAGs and are likely to be important for GAGs neutralisation during coagulation. This section will examine the Zn 2+ and GAG binding properties of these three proteins and how Zn 2+ can influence GAG neutralisation.
Histidine-rich glycoprotein (HRG)
HRG is a single chain protein composed of several structural domains that include a histidine-rich region (HRR). This region is important in both proteins, as neutrally-charged histidine residues bind Zn 2+ via their imidazole side chains. 28, 48 HRG also contains two cystatin-like domains at its N-terminus (N1 and N2) and possesses a C-terminal domain, whilst its histidine-rich region is flanked by two proline-rich regions (Fig. 2) . 55 The 58 When the net charge of HRG becomes positive, either through a change in protonation of the histidine residues (through a change in pH) or through binding of those residues to metal cations, the conformation of the molecule changes, influencing its affinity for binding its ligands. 70 Thus, HRG is an important anticoagulant GAG neutraliser in plasma and this neutralisation is dependent upon the plasma Zn 2+ concentration.
High-molecular weight Kininogen (HMWK)
HMWK is a single chain protein that consists of 6 domains, one of which, domain 5, contains a HRR (Fig. 3) . 54 29, 47 In addition to histidines, this region is rich in lysine residues, which are involved in heparin binding. 29, 47 The heparin binding affinity of HMWK increases when the pH decreases and the histidine residues become protonated, regardless of the presence of cations. 25 UFH and LMWH bind with similar affinity to HMWK in the absence of Zn 2+ but the influence of the heparin chain length on the binding affinity in the presence of Zn 2+ is not yet known. 25 HMWK competes with AT, thrombin or the AT-thrombin complex for heparin-binding and can neutralise the anticoagulant effect of heparin in plasma. 25 However, this binding may not be specific, as HMWK can bind all heparins regardless of whether or not they possess the saccharide sequence used to bind AT with high affinity, and thus several HMWK molecules may be required to fully neutralise one heparin molecule. 25 Maximal neutralisation has been shown to occur in the presence of 10 mM Zn 2+ . 25 In addition, HS proteoglycans located at the cell surface can bind HMWK in a Zn 2+ -dependent manner but the effect of this binding on the anticoagulant activity of HS has not been investigated directly. 50 Thus HMWK appears to neutralise anticoagulant GAG in a similar manner to HRG.
As HMWK is present in plasma at similar levels to HRG and binds heparin with similar affinity (K d in low nanomolar range), Fig. 2 Structure of histidine-rich glycoprotein. N1 and N2 are N-terminal domain 1 and 2, they have a GAG binding activity; PRR1 and PRR2 are proline-rich regions; HRR is the histidine rich region that binds Zn 2+ and GAG; C is the C-terminal domain. Fig. 3 Structure of high-molecular-weight kininogen. Domains 1, 2 and 3 are cystatin-like domains, with 2 and 3 having a cysteine protease inhibitor activity; domain 4 is bradykinin and another peptide; domain 5 is the surface-binding domain containing the histidine-rich region that binds GAGs and Zn
2+
; domain 6 is the domain binding prekallikrein and activated coagulation factor XI.
these proteins may be of equal importance in anticoagulant GAG neutralisation.
Fibrinogen
Fibrinogen is a homodimer composed of two sets of three different polypeptides chains, Aa, Bb and g (Fig. 4) . 72 Most of the protein has been crystallised to some extent, with the exception of the highly variable aC domain (PDB 3GHG). 73 Fibrinogen binds Zn 2+ at two different regions. The first set of binding sites is located in the D-domains (Fig. 4, insert 1 ) and has a stoichiometry of six (three ions per D-domain). 74 The sites predominantly consist of histidine residues located on the g chain, with His-g217 and His-g234 thought to be involved, 74 however the effect of Zn 2+ binding at this region on the conformation of the protein is unknown. Another Zn
2+
-binding region has been identified in the aC-domain and also involves histidine residues (His-a544 and His-a545). 75 Binding of Zn 2+ to this region is thought to induce a change in the conformation of the protein. 75 Based on several studies, Zn 2+ binding to fibrinogen has an average K d of B1-18 mM, but the individual contributions of the two groups of sites are unknown. 27, 36, 75 Two different heparin binding modes have been identified on fibrinogen. The first occurs at a site located on the b chain in the E domain around the Bb1-57 region (Fig. 4, insert 2) . It has been shown that a synthetic peptide corresponding to this exact region binds heparin with a K d of 16.5 mM, 76 whilst a dimer of the peptide, (Bb1-66) 2 exhibits an almost two orders of magnitude higher affinity for heparin (K d of 210 nM), compared to the monomer. 76 . 75 The link between heparin chain length and binding affinity in the presence and absence of Zn 2+ is not yet known. The binding of fibrinogen to heparin participates in the neutralisation of its anticoagulant activity. The direct study of fibrinogen-mediated GAG neutralisation has been complicated by the fact that thrombin cleaves fibrinogen. However, fibrinogen has been shown to be more effective at neutralising DS than HRG (and platelet factor 4). 68 This neutralisation occurs at physiological fibrinogen concentrations and is not affected by the size or the degree of sulfation of DS. 68 The mechanism of neutralisation appears not to occur through direct competition with Crystal structure of fibrinogen D domain (one of the Zn 2+ binding domain) and part of the coil-coil region (PDB structure 3GHG). 73 The histidine residues which have the potential to be involved in Zn 2+ binding are represented in pink with the residues His217 and His234 known to be involved represented in yellow. Most of those residues are hidden beneath the surface of the protein. Insert 2. Crystal structure of fibrinogen E domain (the heparin binding domain) and part of the coil-coil regions, (PDB structure 3GHG). 73 The positive charges are represented in blue and the negative charges in red. The Lys and Arg residues which usually constitutes the main binding partners of GAGs are represented in green. The first few residues of the Bb chain are mobile and so they are not visible in the crystal structure, with b58 the first residue that can be observed (represented in yellow). This residue is a protruding Lys that is believed to be important for GAG binding. As the GAG binding affinity of fibrinogen is enhanced when the protein is converted into fibrin by cleavage of the A and B peptides, the absence in the crystal structure of the first few residues of the Bb chain may be the reason for exposure of the b58 residue. The aC domain is attached to the E domain; binding of Zn 2+ ions to its His a544 and His a545 is thought to change the conformation of the protein and thus facilitate GAG binding to the E domain.
the thrombin-HCII complex for DS binding but by controlling the rate of formation of this complex. 68 In addition, fibrin can also form complexes with heparin, AT and thrombin to reduce thrombin inhibition by AT in a Zn 2+ -dependent manner. 52, 77 Thus, fibrinogen is an important anticoagulant GAG neutraliser, with the plasma concentration of fibrinogen being linked to heparin resistance in patients. 78 The sensitivity of fibrinogen toward plasma Zn 2+ levels relative to HRG and HMWK is not yet known.
Other anticoagulant GAG neutralising proteins
Zn 2+ can also potentially affect the neutralisation of anticoagulant GAGs through, fibronectin, fibroblast growth factors (FGF), FGF-1 and FGF-7 and activated coagulation factor VII (FVIIa). 30, 79, 80 Fibronectin can be found as the alternative spliced forms of cellular or plasma fibronectin. Plasma fibronectin is present in plasma at a concentration of 300-600 nM and is also stored in platelet a-granules and released during coagulation. 81 Cellular fibronectin is synthesised by endothelial cells and can be released into plasma during wound healing. 82 Zn 2+ binding by fibronectin has not yet been fully characterised, however several regions have been shown to bind Zn 2+ in vitro. These include the collagen/gelatin binding domain (binding to which has been shown to elicit a conformational change in this region), 30, 83, 84 the cell binding domain 30 and the alternatively spliced type III connecting segment (IIICS) which is only fully present in cellular fibronectin and a small fraction of plasma fibronectin. 85 It is still unclear whether plasma fibronectin binds Zn 2+ physiologically or whether this only occurs with cellular fibronectin. 85, 86 Considering that Zn 2+ induces a conformational change in the protein and may thus influence GAG binding, this is an important question to answer. Fibronectin possess 5-6 ionic GAG binding sites. 26, 81 The first binding site (often termed Hep1) is found in the N-terminal region. As Zn 2+ binding to the neighbouring gleatin-binding region induces a conformation change in the protein, it is probable that this could impact on GAG binding in Hep1. 83 The second GAG binding region (Hep2) has two distinct GAG binding sites and constitutes the high affinity GAG binding region. 87 As the region is flanked by two Zn 2+ -binding regions, the cell-binding region and the IIICS, Zn 2+ binding may also impact on GAG binding at this site. The global K d of heparin binding to fibronectin is 0.9 mM for a 18-20 saccharide heparin (molecular weight 6000 Da). 87 The affinity for UFH is not yet known. Fibronectin does interfere with AT binding to immobilised heparin as a function of heparin concentration. However AT is only completely displaced from heparin at fibronectin/AT ratios higher than are found physiologically. 81 Fibronectin also binds HS and DS but its effect on their neutralisation is not known. 88, 89 Thus plasma Zn 2+ levels have (at least in theory) the potential to influence GAG binding and neutralisation by fibronectin. This means that fibronectin has the potential to strongly react with the Zn 2+ released during coagulation and to be major GAG-neutralisers during this time. Fibroblast growth factors are present at very low concentrations in plasma (ca. 28-48 pM for FGF-1 and 643 pM for FGF-7), 90, 91 nevertheless they are normally attached to GAGs of the endothelial surface layer and depend on this binding to exert their functions (including oligomerisation, binding to their cognate receptors and transport between cells). 92 Clinical significance of Zn
2+ -induced GAG neutralisation
In addition to being released during injury by epithelial cells and platelets, plasma Zn 2+ levels are also increased in certain disease states (Fig. 1) . Indeed, atherosclerotic plaques are also known to contain up to six-times more Zn 2+ than healthy tissue. useful to consider, specifically as this process impacts on thrombin activation, an event that directly affects both platelet aggregation (through binding to cell surface receptors) and fibrin clot formation (through cleavage of fibrinogen). Indeed, by enhancing the neutralisation of the GAG present in the endothelium surface layer, Zn 2+ induces a change in the natural anticoagulant properties of the endothelium. 10 When coagulation is needed, this participates in the promotion of clotting. However, if Zn 2+ speciation is chronically altered, such as is likely in certain diseases states (atherosclerosis, diabetes, obesity and cancer), then this could affect anticoagulant processes in the endothelium resulting in a pro-or hyper-thrombotic state through enhanced GAG neutralistaion. 10 This phenomenon could also directly affect the efficiency of heparin-based treatments, which are widely used during surgeries and to manage thrombotic complications. 10 In order to confirm this, it would be interesting to measure plasma Zn 2+ levels in patients undergoing heparin treatment and to compare it to their response to this treatment. If such a relationship is confirmed then an option may be to control Zn 2+ levels in those patients rather than to switch to another anticoagulant treatment whose efficiency could also be potentially affected by Zn 2+ .
Conclusion
Zn 2+ plays a major role in the regulation of coagulation that is only starting to be understood. Because of this role, Zn 2+ homeostasis in platelets and its speciation in plasma are especially relevant to the understanding and treatment of blood diseases. In particular, they can affect GAG binding and neutralisation by the platelet-stored proteins HRG, HMWK and fibrinogen. This mechanism is relevant to healthy coagulation processes through the natural anticoagulation properties of the endothelium, but also in anti-thrombotic treatments. Indeed, it may partly explain the observed variability in dose response to heparins and heparin-based drugs. This implies that free plasma Zn 2+ levels need to be monitored in individuals with coagulatory disorders or at-risk of thrombotic events. 
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